• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[通过家庭自我采样对不符合宫颈癌筛查巴氏试验的女性进行人乳头瘤病毒高危型检测。罗讷河口省一项试点项目的结果]

[HPV-Hr detection by home self sampling in women not compliant with pap test for cervical cancer screening. Results of a pilot programme in Bouches-du-Rhône].

作者信息

Piana Lucien, Leandri François-Xavier, Le Retraite Laurence, Heid Patrice, Tamalet Catherine, Sancho-Garnier Hélène

机构信息

Association pour la recherche et le dépistage des cancers du sein, du col de l'utérus et des cancers colorectaux (Arcades), parc Mure, bâtiment A, 16, boulevard des Aciéries, 13010 Marseille, France.

出版信息

Bull Cancer. 2011 Jul;98(7):723-31. doi: 10.1684/bdc.2011.1388.

DOI:10.1684/bdc.2011.1388
PMID:21700548
Abstract

The non-participation to cervical screening is the major determinant in the risk of mortality due to cervical cancer. In France, around 40% of women do not participate to regular screening. The cultural or economic barriers for performing screening by Pap test are numerous; one of the most frequent is the refusal of gynaecological examination. A persistent HPV(HR) infection is a necessary factor for developing cervical cancer. The HPV(HR) testing has a high sensibility to detect high grade cervical intra-epithelial neoplasia (CIN 2-3) and a satisfactory specificity after 30-35 years old. The principal objective of this study was to compare the participation rates in women 35-69 years old who did not perform a Pap test after a first individual invitation, either when an HPV(HR) auto-test was offered to be performed at home or a second invitation to Pap test was sent. We also evaluated the quality of the two tests, the positive results obtained by age groups and the following histological type of lesions diagnosed in the women with positive results. The study included 9,334 women, 35-69 years old, who did not realized a Pap-test during the 2 previous years and who did not respond at a first individual invitation. These non-responders were randomized into two groups: one group (n=4,934) received a second individual invitation and the other (n=4,400) an offer of receiving and performing an HPV auto-test at home. In women 35-69 years the participation to the second invitation to Pap test was significantly lower (7.2%) than the participation to auto-test (26.4%) with P<0.001. The quality of the two tests was satisfactory; the auto-test was not altered by the postage to laboratory (non interpretable rate=1.4% [CI at 95%=0.65%; 2.15%]. From the 311 Pap tests done, 5.5% (17) were classified "abnormal" (nine ASCUS, one high grade and seven low grades). The follow up of 13 women out of 17 confirmed the diagnosis for 1 case of CIN2 and 2 cases of CIN3, 4 women are lost of follow up after 6 months. From the 939 HPV(HR) tests done, 6.2% (58) were positive. Such positivity rate was not influenced by age. Out of the 58 positive HPV(HR) cases, 27 only were of the 16 genotype (46.5% [CI 95%=33.7%; 59.3%]). This law rate is a consequence of an inversion of the ratio HPV 16 versus other types in women 60 years old and over. In this group, the follow-up of 36 women diagnosed five cases of CIN1, one of CIN2 and four of CIN3; 22 patients are lost of follow up at 6 months. Globally, in the studied population, an individual recall for pap test allowed to diagnose and treat 3 high grade lesions (7‰) and the dispatching of an auto test allowed the diagnosis and treatment of five high grade lesions (1,4‰), this difference is significant (P=0.02; OR=0.25 [0.05; 0.97]). The HPV(HR) auto-test seems to be better accepted than the Pap test in the 35-69 years old women previously non-responders to individual invitation, and the quality of the test is satisfactory. Such a test can be proposed to the 35-69 years old non-participant to Pap test to increase the coverage for cervical screening, if the rates of diagnostic examinations performed in case of an HPV(HR) positive is sufficiently high.

摘要

未参加宫颈癌筛查是宫颈癌死亡风险的主要决定因素。在法国,约40%的女性未参加定期筛查。进行巴氏试验筛查存在诸多文化或经济障碍;最常见的障碍之一是拒绝妇科检查。持续性高危型人乳头瘤病毒(HPV)感染是宫颈癌发生的必要因素。高危型HPV检测对检测高级别宫颈上皮内瘤变(CIN 2 - 3)具有高敏感性,在30 - 35岁之后特异性良好。本研究的主要目的是比较35 - 69岁女性在首次个人邀请后未进行巴氏试验的情况下,提供在家自行进行高危型HPV检测或再次邀请进行巴氏试验时的参与率。我们还评估了两种检测的质量、按年龄组获得的阳性结果以及阳性结果女性中确诊的病变组织学类型。该研究纳入了9334名35 - 69岁的女性,她们在过去两年未进行巴氏试验且对首次个人邀请未回应。这些未回应者被随机分为两组:一组(n = 4934)收到再次个人邀请,另一组(n = 4400)收到在家自行进行高危型HPV检测服务。在35 - 69岁女性中,对再次巴氏试验邀请的参与率(7.2%)显著低于自行检测的参与率(26.4%),P < 0.001。两种检测质量均令人满意;自行检测不受邮寄至实验室的影响(无法解读率 = 1.4% [95%置信区间 = 0.65%;2.15%])。在311次巴氏试验中,5.5%(17例)被分类为“异常”(9例非典型鳞状细胞不能明确意义、1例高级别和7例低级别)。17例中的13例女性进行随访,确诊1例CIN2和2例CIN3,4例女性在6个月后失访。在939次高危型HPV检测中,6.2%(58例)为阳性。该阳性率不受年龄影响。在58例高危型HPV阳性病例中,仅27例为16型(46.5% [95%置信区间 = 33.7%;59.3%])。该低比例是60岁及以上女性中HPV 16型与其他类型比例倒置的结果。在该组中,36例女性进行随访,确诊5例CIN1、1例CIN2和4例CIN3;22例患者在6个月后失访。总体而言,在研究人群中,个人召回进行巴氏试验可诊断和治疗3例高级别病变(7‰),发放自行检测可诊断和治疗5例高级别病变(1.4‰),差异具有统计学意义(P = 0.02;OR = 0.25 [0.05;0.97])。对于之前对个人邀请未回应的35 - 69岁女性,高危型HPV自行检测似乎比巴氏试验更易被接受,且检测质量令人满意。如果高危型HPV阳性时进行诊断性检查的比例足够高,可向35 - 69岁未参加巴氏试验的女性提供此类检测,以提高宫颈癌筛查覆盖率。

相似文献

1
[HPV-Hr detection by home self sampling in women not compliant with pap test for cervical cancer screening. Results of a pilot programme in Bouches-du-Rhône].[通过家庭自我采样对不符合宫颈癌筛查巴氏试验的女性进行人乳头瘤病毒高危型检测。罗讷河口省一项试点项目的结果]
Bull Cancer. 2011 Jul;98(7):723-31. doi: 10.1684/bdc.2011.1388.
2
Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.自我采样的短时间内重复高危型 HPV 检测在宫颈癌筛查中的应用。
Br J Cancer. 2011 Aug 23;105(5):694-7. doi: 10.1038/bjc.2011.277. Epub 2011 Aug 2.
3
Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.高危型人乳头瘤病毒 DNA 检测作为宫颈癌筛查计划中的主要检测方法:一项基于人群的队列研究。
BJOG. 2013 Sep;120(10):1260-7; discussion 1267-8. doi: 10.1111/1471-0528.12272. Epub 2013 Jun 21.
4
The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.英格兰原发性人乳头瘤病毒子宫颈筛查的临床效果和成本效益:通过三轮筛查对 ARTISTIC 随机试验队列进行的扩展随访。
Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.
5
A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.在墨西哥常规社会保障计划中对 50159 名妇女进行 HPV DNA 和细胞学检测的初步研究。
Cancer Causes Control. 2010 Oct;21(10):1693-700. doi: 10.1007/s10552-010-9598-2. Epub 2010 Jul 9.
6
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.25 岁及以上女性宫颈癌筛查中致癌型人乳头瘤病毒(HPV)检测及 HPV16 或 HPV18 基因分型的性能:ATHENA 研究的一项亚组分析。
Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.
7
Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.人乳头瘤病毒(HPV)检测在巴氏涂片异常女性管理中的应用。一家阴道镜转诊诊所的经验。
Eur J Gynaecol Oncol. 2004;25(5):577-84.
8
HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.HPV 检测与常规细胞学检查在宫颈癌筛查中的比较:ARTISTIC RCT 的长期随访。
Health Technol Assess. 2019 Jun;23(28):1-44. doi: 10.3310/hta23280.
9
Cytology versus HPV testing for cervical cancer screening in the general population.普通人群宫颈癌筛查中细胞学检查与HPV检测的比较
Cochrane Database Syst Rev. 2017 Aug 10;8(8):CD008587. doi: 10.1002/14651858.CD008587.pub2.
10
Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening.50 岁及以上未参加巴氏涂片筛查的女性的阴道液自我采样和高危型人乳头瘤病毒检测。
BJOG. 2012 Jan;119(2):245-8. doi: 10.1111/j.1471-0528.2011.03147.x. Epub 2011 Oct 21.

引用本文的文献

1
An outreach strategy to increase uptake of vaginal self-sampling for cervical cancer screening in older French women: The RIDECA interventional research protocol.一项旨在提高法国老年女性接受阴道自我采样宫颈癌筛查的外展策略:RIDECA 干预性研究方案。
Womens Health (Lond). 2024 Jan-Dec;20:17455057241292693. doi: 10.1177/17455057241292693.
2
Offering HPV self-sampling kits: an updated meta-analysis of the effectiveness of strategies to increase participation in cervical cancer screening.提供 HPV 自我采样试剂盒:增加宫颈癌筛查参与度策略有效性的更新荟萃分析。
Br J Cancer. 2023 Mar;128(5):805-813. doi: 10.1038/s41416-022-02094-w. Epub 2022 Dec 14.
3
HPV Self-Sampling for Cervical Cancer Screening among Women Living with HIV in Low- and Middle-Income Countries: What Do We Know and What Can Be Done?
低收入和中等收入国家感染艾滋病毒女性的宫颈癌筛查人乳头瘤病毒自我采样:我们了解什么以及能做什么?
Healthcare (Basel). 2022 Jul 8;10(7):1270. doi: 10.3390/healthcare10071270.
4
Acceptability of Human Papilloma Virus Self-Sampling for Cervical Cancer Screening in a Cohort of Patients from Romania (Stage 2).罗马尼亚一组患者中用于宫颈癌筛查的人乳头瘤病毒自我采样的可接受性(第2阶段)。
J Clin Med. 2022 Apr 29;11(9):2503. doi: 10.3390/jcm11092503.
5
Interventions targeted at women to encourage the uptake of cervical screening.针对女性的干预措施,以鼓励她们接受宫颈癌筛查。
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
6
Mailed self-sample HPV testing kits to improve cervical cancer screening in a safety net health system: protocol for a hybrid effectiveness-implementation randomized controlled trial.邮寄自采样 HPV 检测试剂盒以改善安全网卫生系统中的宫颈癌筛查:一项混合有效性-实施随机对照试验的方案。
Trials. 2020 Oct 21;21(1):872. doi: 10.1186/s13063-020-04790-5.
7
Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis.人乳头瘤病毒(HPV)检测的自我采样:一项系统评价和荟萃分析。
BMJ Glob Health. 2019 May 14;4(3):e001351. doi: 10.1136/bmjgh-2018-001351. eCollection 2019.
8
Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.利用 HPV 自我采样检测来发现宫颈癌前病变并覆盖未筛查人群:更新的荟萃分析。
BMJ. 2018 Dec 5;363:k4823. doi: 10.1136/bmj.k4823.
9
Self-Sampling for Human Papillomavirus Testing: Increased Cervical Cancer Screening Participation and Incorporation in International Screening Programs.人乳头瘤病毒检测的自我采样:提高宫颈癌筛查参与率并纳入国际筛查项目。
Front Public Health. 2018 Apr 9;6:77. doi: 10.3389/fpubh.2018.00077. eCollection 2018.
10
Attitudes and factors affecting acceptability of self-administered cervicovaginal sampling for human papillomavirus (HPV) genotyping as an alternative to Pap testing among multiethnic Malaysian women.在马来西亚多民族女性中,影响自我采集宫颈阴道样本进行人乳头瘤病毒(HPV)基因分型以替代巴氏试验的可接受性的态度和因素。
BMJ Open. 2016 Aug 4;6(8):e011022. doi: 10.1136/bmjopen-2015-011022.